AstraZeneca PLC (AZN)vsWarby Parker Inc (WRBY)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
WRBY
Warby Parker Inc
$24.71
+1.69%
HEALTHCARE · Cap: $3.04B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 6632% more annual revenue ($61.37B vs $911.61M). AZN leads profitability with a 17.0% profit margin vs 0.8%. AZN trades at a lower P/E of 24.3x. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
WRBY
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
-5.9%
Fair Value
$20.77
Current Price
$24.71
$3.94 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
No standout strengths identified
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Trading at 8.1x book value
ROE of 0.4% — below average capital efficiency
0.8% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : WRBY
WRBY has a balanced fundamental profile.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : WRBY
The primary concerns for WRBY are Price/Book, Return on Equity, Profit Margin. A P/E of 409.5x leaves little room for execution misses. Thin 0.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
AZN profiles as a mature stock while WRBY is a value play — different risk/reward profiles.
WRBY carries more volatility with a beta of 1.91 — expect wider price swings.
WRBY is growing revenue faster at 9.8% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 30/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Warby Parker Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Warby Parker Inc. (WRBY) is an innovative direct-to-consumer eyewear company that has redefined the eyewear shopping experience since its inception in 2010. With a successful blend of e-commerce and physical retail expansion, the company offers stylish and affordable prescription glasses and sunglasses, appealing to a broad demographic. Warby Parker is distinguished by its commitment to social responsibility, exemplified by its "Buy a Pair, Give a Pair" initiative, which underscores its dedication to making a positive impact. As the company leverages its strong brand reputation and effective marketing strategies, it is well-positioned for continued growth in the increasingly competitive eyewear sector, addressing evolving consumer preferences while enhancing its social mission.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?